USO 21225
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens (ACE-Breast-03)
Disease Types: Breast Cancer Research
Eligibility Requirements:
-Her 2+ metastatic breast cancer with measurable disease, must have prior therapy with ado-trastuzumab (T-DM1), and/or trastuzumab deruxtecan (T-Dxd), and/or tucatinib containing regimen, and trastuzumab + taxane.
-No: clinically significant lung disease within the last 12 months, history of interstitial lung disease or pneumonitis; congestive heart failure, unstable angina, unstable atrial fibrillation, or cardiac arrhythmia in the last 12 months and myocardial infarction within last 6 months; unstable central nervous metastasis; peripheral neuropathy grade 2 or higher; known active HIV, Hep B, or Hep C; or ocular conditions such as keratopathy, dry eye, keratitis, corneal disorders, or current ocular infection.
Available at: